Predictive Value of Baseline Plasma D-dimers for Chemotherapy-induced Thrombocytopenia in Patients with Stage III Colon Cancer: A Pilot Study

Tanrıverdi, Özgür

doi:10.7314/apjcp.2013.14.1.293

Cited by 9 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The performance characteristics of the model were sensitivity 56%, specificity 88%, positive likelihood ratio 4.63, and negative likelihood ratio 0.50. In another study, Tanriverdi 14 presented a predictive model based on a single laboratory variable of baseline plasma D-dimer level (an important marker of thrombotic activity) for CIT in patients with stage III colon cancer. Model performance characteristics were sensitivity 91.4%, specificity 89.7%, positive likelihood ratio 3.64, and negative likelihood ratio 0.24.…”

Section: Discussionmentioning

confidence: 99%

“…To the best of our knowledge, there is no evidence of direct association of these factors with CIT in the earlier related studies. [10][11][12][13][14][15][16] Several studies have reported a significant association between high ferritin and chemotherapy-induced hematologic consequences. 17,18,[26][27][28] There is some evidence that iron or ferritin has suppressive effects on hematopoietic cell proliferation and differentiation.…”

Section: Discussionmentioning

confidence: 99%

“…In these studies, the main covariates included age, type of chemotherapy regimen, prior chemotherapy or surgery, platelet count, lymphocyte count, body surface area, hematocrit, albumin, bone marrow metastases, diabetes, pulmonary disease, treatment with a drug affecting platelet function, prior episode of bleeding, performance status, Helicobacter pylori infection, level of plasma D-dimer, and blood group. [10][11][12][13][14][15][16] Development of predictive models for chemotherapyinduced hematologic toxicities based on simple and cost-effective markers could have substantial clinical value. In our recent studies, some laboratory and clinical predictors of hematologic toxicities (i.e.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

Razzaghdoust

Mofid

Zangeneh

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose Chemotherapy-induced thrombocytopenia is a serious complication in chemotherapy-treated patients. Identification of patients at risk for chemotherapy-induced thrombocytopenia could have clinical value in personalized management of patients and optimized administration of prophylactic thrombopoietic agents. The aim of this study was to develop a predictive model for chemotherapy-induced thrombocytopenia (platelet count < 100,000/µl) in cancer patients undergoing chemotherapy. Methods A total of 14 covariates were prospectively assessed as explanatory variables in a cohort of consecutive patients with solid tumors or lymphoma. A multivariable logistic regression model was developed after univariable analysis. A bootstrapping technique was applied for internal validation. Results Data from 305 patients during 1732 chemotherapy cycles were considered for analysis. Forty-eight patients (15.73%) developed chemotherapy-induced thrombocytopenia during their treatment course. The multivariable model exhibited three final predictors for chemotherapy-induced thrombocytopenia, including high ferritin (odds ratio, 4.41; bootstrap P = 0.001), estimated glomerular filtration rate <60 ml/min/1.73 m2 (odds ratio, 3.08; bootstrap P = 0.005), and body mass index <23 kg/m2 (odds ratio, 2.23; bootstrap P = 0.044). The main characteristics of the model include sensitivity 75%, specificity 65.4%, positive likelihood ratio 2.16, and negative likelihood ratio 0.382. Moreover, the model was well calibrated (Hosmer–Lemeshow P = 0.713) and the area under the receiver operating characteristic curve was 0.735 (95% confidence interval, 0.654–0.816; P < 0.001). Conclusions We developed a predictive model for chemotherapy-induced thrombocytopenia based on readily available and easily assessable clinical and laboratory factors. This study may provide a valuable insight to guide optimized treatment of cancer patients. Further studies with larger sample size are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

Razzaghdoust

Mofid

Zangeneh

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…The article entitled "Predictive Value of Baseline Plasma D-dimers for Chemotherapy-induced Thrombocytopenia in Patients with Stage III Colon Cancer: A Pilot Study" written by Tanriverdi (2013) and published in one of the recent issues of your journal was quite interesting. Here, we would like to emphasize some points.…”

Section: Dear Editormentioning

confidence: 99%

Malignancies and Disseminated Intravascular Coagulation

Yavaşoğlu¹

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Chemotherapy-induced thrombocytopenia can occur via different mechanisms, either by suppressing megakaryopoiesis, which prevents platelet production, or by directly damaging the platelets. Chemotherapies like antimetabolites and alkylating agents can induce severe thrombocytopenia as they cause bone marrow suppression, specifically after the first cycle of chemotherapy [9][10][11][12][13][14][15]. The incidence and severity of thrombocytopenia mainly depend on factors such as chemotherapy, chemotherapy schedule, chemotherapy intensity, and type of cancer.…”

Section: Introductionmentioning

confidence: 99%

Association and Correlation of Different Chemotherapy Regimens and Doses with Incidence and Severity of Thrombocytopenia among Solid Cancer Patients

Yusoff

Wayyes

Hareeja

et al. 2021

Al-Rafidain J Med Sci

View full text Add to dashboard Cite

Background: Thrombocytopenia is an abnormal decrease in platelet numbers and is a major detrimental side effect of chemotherapy or of cancer itself. Thrombocytopenia can lead to hemorrhage in vital organs, which is particularly a problematic specifically in solid cancer patients, and has a substantial negative effect on cancer patients’ quality of life (QOL). Thrombocytopenia ranges from mild bleeding from small blood vessels to severe bleeding from large blood vessels. Objectives: The present study aimed to describe the effect of chemotherapy regimens and doses on thrombocytopenia incidence and severity among solid cancer patients with thrombocytopenia. Materials and Methods: This retrospective observational study was conducted in Penang Hospital, a government hospital on Penang island, and included 341 cancer patients with thrombocytopenia who were admitted between 2003 and 2009. The main statistical tests used were the Chi-square test and logistic regression. The level of significance was set at P < 0.05. Results: Of the 341 patients included, 21 (6.2%) had thrombocytopenia before chemotherapy and the remaining 320 (93.8%) developed it after chemotherapy. The majority of patients had moderate thrombocytopenia (n=172; 53.8%), followed by mild (n=97; 30.3%), and severe thrombocytopenia (n=51; 15.9%). FEC, 5-FU+5-FU, Docetaxel and Cisplatin regimen had strong associations and correlation with thrombocytopenia incidence and severity, but the associations and correlations for thrombocytopenia severity were stronger than those for incidence. The dosage of 5-FU, cyclophosphamide, docetaxel and cisplatin plays a critical role in thrombocytopenia incidence and severity. Conclusion: Monitoring and determination of hemoglobin levels for cancer patients treated with FEC, 5-FU+5-FU, Docetaxel, and Cisplatin specifically with high doses must be emphasized and a focus of particular attention.

show abstract

Predictive Value of Baseline Plasma D-dimers for Chemotherapy-induced Thrombocytopenia in Patients with Stage III Colon Cancer: A Pilot Study

Cited by 9 publications

References 18 publications

Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

Malignancies and Disseminated Intravascular Coagulation

Association and Correlation of Different Chemotherapy Regimens and Doses with Incidence and Severity of Thrombocytopenia among Solid Cancer Patients

Contact Info

Product

Resources

About